Furthermore, several studies recommend the evaluation of the CD8 + /FOXP3 + ratio of TILs as sensitive markers of tumor immune responses in breast cancer rather than evaluation of FOXP3 + or CD8 + TILs alone [25–29]. This evidence concerns the gene CD8A and breast carcinoma.